Myelodysplastic Syndromes
Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
Melissa BadamoMyelodysplastic Syndromes | November 20, 2024
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | November 19, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept.
Jamile Shammo, MDMyelodysplastic Syndromes | November 18, 2024
Is ESA use and performance in the academic setting reflective of real-world MDS practice? Our expert panel discusses.
Jamile Shammo, MDMyelodysplastic Syndromes | November 18, 2024
The panel discusses how to best implement such a monitoring system to address a widespread issue of suboptimal dosing.
Melissa BadamoMyelodysplastic Syndromes | November 18, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | November 15, 2024
The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024.
Advertisement
Jamile Shammo, MDMyelodysplastic Syndromes | November 15, 2024
The panel led by Jamile Shammo, MD, reacts to results from a claims database study comparing the agent with ESAs.
Melissa BadamoMyelodysplastic Syndromes | November 14, 2024
In the next roundtable segment, the panel discusses risk stratifying patients with the IPSS-R and IPSS-M.
Melissa BadamoMyelodysplastic Syndromes | November 13, 2024
An expert panel discusses how to measure the MDS patient experience and whether it’s time for new endpoints in MDS.
Melissa BadamoMyelodysplastic Syndromes | November 4, 2024
More patients receiving luspatercept versus epoetin alfa saw improvements in erythroid, neutrophil, and platelet lineages.
Melissa BadamoMyelodysplastic Syndromes | November 1, 2024
More patients treated with luspatercept had improvement or resolution of neutropenia and thrombocytopenia, she said.
Jamile Shammo, MDMyelodysplastic Syndromes | October 29, 2024
The expert panel discussion led by Jamile Shammo, MD, also noted differences in cell line suppression by mutational profile.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
A novel multivariate model improved risk stratification in MDS compared with both the IPSS-R and IPSS-M.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
The rate of abnormal cytogenetics among AA patients with MDS is comparable to or lower than the general population.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
CDC database analysis suggests that MDS-related mortality has declined since 2011, though significant disparities remain.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
The COMMANDS study compared the efficacy of luspatercept with epoetin alfa in ESA-naïve lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | October 25, 2024
The researchers found a perfect correlation between the AI-based multiparametric flow cytometry score and the IPSS-M.
Melissa BadamoMyelodysplastic Syndromes | October 25, 2024
Discrepancies between the WHO and ICC classification systems for MDS can create inconsistencies in a clinical setting.
Melissa BadamoMyelodysplastic Syndromes | October 25, 2024
Through genomic profiling, researchers identified 18 MDS subtypes associated with clinical outcomes.
Valeria Santini, MDMyelodysplastic Syndromes | October 24, 2024
At EHA 2024, Dr. Santini shares data on luspatercept and imetelstat in patients with MDS and anemia.
Advertisement
Advertisement
Editorial Board